Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Q3 2024 Earnings Presentation
25 slides from Modus Therapeutics Holding Ab's earnings presentation, Nov 19, 2024
Slide 1: Interim Report for the Third Quarter 2024
MODUS THERAPEUTICS INTERIM REPORT FOR THE THIRD QUARTER 2024 January - September 2024 1
Slide 2: The Quarter in Brief
THE QUARTER IN BRIEF | JANUARY 1 - SEPTEMBER 30 2O24 Interim report for the third quarter 2024 The third quarter in figures Important events during the third quarter Important events after the end of the period • The loss after tax amounted to TSEK 2 989 • Board Member Torsten Goesch passed away. •
Slide 3: CEO Statement: Strategic Advances and Clinical Renewal
CEO STATEMENT Strategic Advances and Clinical Renewal for Modus Therapeutics The third quarter of 2024 has been marked by both significant progress and focused work for Modus Therapeutics. We continue to advance our mission of bringing innovative treatments to high need patients, with major mileston
Slide 4: CEO Statement
CEO STATEMENT peutics secured access to bridge financing and General Counsel at Karolinska Develop- gy-2024/programme) . Sharing our findings of 5MSEK from our largest and longest-term ment AB, and we look forward to his contribu- with the scientific community is crucial as we investor, Karolinska D
Slide 5: About Modus Therapeutics
STATEMENT OF OPERATIONS About Modus Therapeutics Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inf
Slide 6: Modus pipeline
STATEMENT OF OPERATIONS Modus pipeline INDICATION DEVELOPMENT Preclinical Phase Ia Phase Ib Phase IIa Phase IIb Phase III Sepsis Modus Sepsis/Septic chock Planning Phase IIa Anemia* Modus Anemia chronic inflammation/kidney disease Before start Phase Malaria Collaboration** Severa malaria (ongoing st
Slide 7: Preclinical research suggests that sevuparin...
STATEMENT OF OPERATIONS These robust results from preclinical cellular and ani- mal models as well as human subjects demonstrate sevuparin’s ability to suppress hepcidin at clinically safe dose levels and provide strong evidence of its ability to modulate hepcidin expression. In addition, data from
Slide 8: Completed studies support phase 2 development in sepsis and anemia
STATEMENT OF OPERATIONS Completed studies support phase 2- Plasma hepcidin development in sepsis and anemia in decreased to 30-50% of baseline values chronic disease in the presence of Sevuparin, with maximal Sevuparin has been shown to be safe and tolerable with single and multiple suppression betw
Slide 9: Market overview
STATEMENT OF OPERATIONS Market overview With sevuparin, Modus primarily target three challanging indications - sepsis, anemia and severe malaria. Sevuparin has significant potential within the markets for these indication, which are mainly driven by the significant medical need and the increasing gl
Slide 10: Anemia in chronic kidney disease
STATEMENT OF OPERATIONS Anemia in chronic kidney disease Anemia is a global health issue affecting approxi- mately 2.3 billion people, which represents 25% of the world’s population. The most common form of anemia is iron deficiency anemia, impacting nearly one billion individuals. Chronic kidney di
Slide 11: Severe malaria
STATEMENT OF OPERATIONS Severe malaria Severe malaria is a rapidly progressing and serious condition resembling sepsis, primarily affecting young children, with a mortality rate of 10-20%. While available standard treatments are effective given time to start working, there is a lack of an adjuvant t
Slide 12: Development of profit and financial position
FINANCIAL REPORT Development of profit and financial position Third quarter First 9- months Operating profit/loss Operating profit/loss Operating loss for the period July-September Operating loss for the period January- 2024 amounted to TSEK 2 989 (2 456). September 2024 amounted to TSEK 10 The cost
Slide 13: Important events during and after the quarter
FINANCIAL REPORT Important events during Conferance in Copenhagen, Denmark on October 6-7. parts. Part 1 aims to establish dosage levels and safety of sevuparin through single doses the quarter in 25-30 patients with varying degrees of kidney failure. Part 1 will also include a small Board member To
Slide 14: Other disclosures
FINANCIAL REPORT Other disclosures Ownership structure (555). The loss for the period amounted to Group’s cash and cash equivalents amoun- At the end of the fourth quarter, there were TSEK 4 712 (5 969). The company’s net sales ted to SEK 8,0 million. 962 shareholders in Modus Therapeutics consist o
Slide 15: Financial report: funding and risks
FINANCIAL REPORT to this funding enables Modus to maintain ty, as well as Modus. The general decline in momentum in its research and initiate the re- the stock market and the rise in interest rates cently approved Phase IIa study for chronic could affect Modus and its financing oppor- kidney disease
Slide 16: Consolidated summary income statement
FINANCIAL REPORT Consolidated summary income statement 2024 2023 2024 2023 2023 TSEK Jul 1 - Sep 30 Jul 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Dec 31 Net sales - - - - - Research and development costs -1 818 -990 -6 214 -7 243 -8 482 Administration costs -1 149 -1 483 -4 748 -5 297 -7 831
Slide 17: Consolidated summary balance sheet
FINANCIAL REPORT Consolidated summary balance sheet 2024 2023 2023 TSEK Sep 30 Sep 30 Dec 31 Assets Fixed assets Other financial fixed assets 51 50 51 Total fixed assets 51 50 51 Current assets Other receivables 560 1 369 930 Cash equivalents 7 999 3 867 19 060 Total current assets 8 559 5 235 19 99
Slide 18: Consolidated change in shareholders' equity in summary
FINANCIAL REPORT Consolidated change in shareholder’s equity in summary 2024 2023 2024 2023 2023 TSEK Jul 1 - Sep 30 Jul 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Dec 31 Opening balance equity 9 838 -13 320 17 681 -2 585 -2 585 Profit/loss for the period -2 989 -3 093 -10 831 -13 828 -17 897
Slide 19: Consolidated cash flow statement in summary
FINANCIAL REPORT Consolidated cash flow statement in summary 2024 2023 2024 2023 2023 TSEK Jul 1 - Sep 30 Jul 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Dec 31 Operating activities Operating profit/loss -2 989 -2 456 -10 992 -12 629 -16 401 Interest received 0 1 160 1 3 Interest paid - - - - -
Slide 20: Parent company income statement in summary
FINANCIAL REPORT Parent company income statement in summary 2024 2023 2024 2023 2023 TSEK Jul 1 - Sep 30 Jul 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Sep 30 Jan 1 - Dec 31 Net sales 185 185 555 555 740 Research and development costs -319 -327 -766 -1 008 -1 419 Administration costs -1 213 -1 228 -1 085 -4
Slide 21: Parent company balance sheet in summary
FINANCIAL REPORT Parent company balance sheet in summary 2024 2023 2023 TSEK Sep30 Sep 30 Dec 31 Assets Non-current assets Financial assets 70 051 70 050 70 051 Total non-current assets 70 051 70 050 70 051 Current assets Other receivables 327 1 223 762 Cash equivalents 7 502 3 412 18 381 Total curr
Slide 22: Notes to the financial reports in summary
FINANCIAL REPORT Notes to the financial reports in summary Note 1 | Accounting principles Note 3 | Incentive program Note 4 | Equity Modus Therapeutics Holding AB’s consoli- The ”Incentive Program 2021/2024” has The share capital of the Parent Company dated accounts have been prepared in expired. No
Slide 23: Financial calendar and Signatures
FINANCIAL REPORT Financial calendar Signatures Interim Report Q3 2024 The Board of Directors and the CEO provide their assurance that this interim | November 20th, 2024 report provides an accurate view of the operations, position and earning of the group and the parent company, and that it also desc
Slide 24: Quarterly overview and Definitions
FINANCIAL REPORT Quarterly overview 2024 2023 2022 THE GROUP Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Net sales, TSEK - - - - - - - - Operating profit, TSEK -2 989 -4 804 -3 199 -3 771 -2 456 -4 365 -5 808 -9 121 Equity/Asset ratio, % 80% 79% 91% 88% -311% -238% -117% -23% Cash equivalents, TSEK 7 999 11 971 15 395
Slide 25: Contact
CONTACT Olof Palmes gata 29 IV John Öhd, CEO 111 22 Stockholm +46(0)70-766 80 97 Sweden john.ohd@modustx.com +46(0)8-502 492 53 Claes Lindblad, CFO & Head of IR ir@modustx.com +46(0)70-246 75 54 www.modustx.com ir@modustx.com 25
Modus Therapeutics Holding — Q3 2024 Earnings Presentation on 6ix